Introduction: The detection rate for significant prostate cancer of extended vs saturation vs mMRI/TRUS fusion biopsy was prospectively evaluated in men enrolled in active surveillance (AS) protocol. Mterials and methods: From May 2013 to September 2016 75 men aged 66 years (median) with very low risk PCa were enrolled in an AS protocol and elegible criteria were: life expectancy greater than 10 years, cT1C, PSA below 10 ng/ml, PSA density < 0.20, 2 < unilateral positive biopsy cores, Gleason score (GS) equal to 6, greatest percentage of cancer (GPC) in a core < 50%. All patients underwent 3.0 Tesla pelvic mpMRI before confirmatory transperineal extended (20 cores) or saturation biopsy (SPBx; 30 cores) combined with mpMRI/TRUS fusion targeted biopsy (4 cores) of suspicious lesions (PI-RADS 3-5). Results: 21/75 (28%) patients were reclassified by SPBx based on upgraded GS ≥ 7; mpMRI lesions PI-RADS 4-5 vs PI-RADS 3-5 diagnosed 9/21 (42.8%) vs 16/21 (76.2%) significant PCa with 2 false positives (6.5%). The detection rate for significant PCa was equal to 76.2% (mpMRI/TRUS fusion biopsy) vs 81% (extended) vs 100% (SPBx) (p = 0.001); mpMRI/TRUS targeted biopsy and extended biopsy missed 5/21 (23.8%) and 4/21 (19%) significant PCa which were found by SPBx (p = 0.001) being characterised by the presence of a single positive core of GS ≥ 7 with GPC < 10%. Conclusions: Although mpMRI improve the diagnosis of clinically significant PCa, SPBx is provided of the best detection rate for PCa in men enrolled in AS protocols who underwent confirmatory biopsy.
ing (4). Recently, multi-parametric Magnetic Resonance Imaging (mpMRI) and mpMRI/TRUS fusion targeted biopsy have improved the accuracy of standard prostate biopsy schemes in the diagnosis of clinically significant PCa especially if located in the anterior prostate (5-7); therefore many authors suggest including mpMRI in AS follow up (8) (9) (10) (11) (12) (13) . However, the time of confirmatory biopsy has been established 6-12 months from initial diagnosis there are no data regarding the number of cores and the best procedure to diagnose exclusively clinically significant PCa. In our study, the detection rate for PCa at confirmatory prostate biopsy has been prospectively evaluated performing mpMRI/TRUS fusion targeted biopsy vs extended or saturation prostate biopsy in men enrolled in a AS protocol study.
MATERIALS AND METHODS
From May 2013 to September 2016 75 men aged between 58 and 73 (median age 66) with very low risk PCa were enrolled in our AS protocol study. Presence of the following criteria defined eligibility: life expectancy greater than 10 years, clinical stage T1C, PSA below 10 ng/ml, PSA density (PSA-D) < 0.20, < 2 unilateral positive biopsy cores, Gleason score (GS) equal to 6, maximum core percentage of cancer (GPC) < 50%. All patients were requested to sign a written informed consent, and six months after PCa diagnosis underwent digital rectal examination, total PSA, PSA-D, PSA doubling time measurement and pelvic mpMRI 3.0 Tesla evaluation before confirmatory trans-perineal prostate saturation biopsy (SPBx); the procedure was performed with the use of a GE Logiq P6 ecograph (General Electric; Milwaukee, WI) supplied with a bi-planar trans-rectal probe (5-7.5 MHz) using a tru-cut 18 gauge needle (Bard; Covington, GA) under sedation and antibiotic prophylaxis (14) . All mpMRI examinations were performed using a 3.0 Tesla scanner, (ACHIEVA 3T; Philips Healthcare Best, the Netherlands) equipped with surface 16 channels phasedarray coil placed around the pelvic area with the patient in the supine position; multi-planar turbo spin-echo T2- 
INTRODUCTION
Active surveillance (AS) has become an alternative (1) (2) (3) to definitive treatment of low/very low risk prostate cancer (PCa), focusing on prevention of overtreatment (1) and strict monitoring over time of patients to establish potential risk reclassification. However, follow-up in the majority of AS protocols is still short, and prospective validation of criteria for selecting low-risk disease is still lack-weighted (T2W), axial diffusion weighted imaging (DWI), axial dynamic contrast enhanced (DCE) and spectroscopy were performed for each patient. The mpMRI lesions characterized by a PI-RADS (Prostate Imaging-Reporting and Data System) score of 4 and 5 were considered highly suspicious for cancer (6, 7) ; two radiologists (AF, GP) blinded to pre-imaging clinical parameters evaluated the MRI data separately and independently. In the presence of mpMRI lesions suggestive of cancer (PI-RADS 3-5), targeted MRI/TRUS fusion guided-biopsies were added to standard SPBx using a GE Logiq E9 (General Electric; Milwaukee, WI) or Hitachi Arietta 70 ecograph (Hitachi Medico, Chiba, Japan) supplied with a end-fire ( Figure 1 ) or biplanar transrectal ( Figure 2 ) probe, respectively. Risk reclassification at repeat biopsy triggered the recommendation for active treatment and defined as over 3 or more than 10% of positive cores, GS > 6, GPC > 50%; patients being reclassified underwent definitive treatment (radical prostatectomy or external radiotherapy). We evaluated the detection rate for clinically significant PCa performing extended biopsy (20 cores: 16 in the periphery and 4 in the anterior zone) vs saturation biopsy (30 cores: 24 in the periphery and 6 in the anterior zone) vs mpMRI/TRUS fusion guided-biopsies (4 targeted cores of the suspicious lesions with PI-RADS 3-5). Probability level of p < 0.05 was considered statistically significant.
RESULTS
The clinical parameters of the 75 patients enrolled in the AS protocol are listed in the Table 1 . 21/75 (28%) patients had unfavourable repeat SPBx and were reclassified based on upgraded GS (15 cases GS = 3 + 4; 4 cases GS = 4 + 3; 2 cases GS = 4 + 4) and number of positive cores (range: 3-5 positive cores; 50% of the cases). In detail, 8 (38%) PCa were located only in the anterior zone of the gland, 8 (38%) in the periphery zone and 5 (24%) in both zones. Of the remaining 54 (72%) patients, 33 were found to have very low-risk PCa and in 21 cancer was absent; PCa was located in the periphery in 22 terised by GS ≥ 7 (100% of the cases) and a number of positive core > 3 (50% of the cases) with 2 false positives (6.5%). The detection rate for significant PCa was equal to 76.2% (mpMRI/TRUS fusion biopsy) vs 81% (16 p (1) is equal to 28% (415/2494 cases). Although the optimal number of cores (extended vs saturation biopsy) and approach of prostate biopsy (trans-rectal vs trans-perineal) has not been established (16), the criteria of reclassification include upgrading (GS ≥ 7) and modification of biopsy quantitative histology (number of positive cores, GPC > 50%). SPBx in comparison with extended biopsy (17) demonstrated more accurate assessment of the extent and grade of disease in men enrolled in AS protocol; in addition, the trans-perineal free hand or template SPBx increases progression to treatment in AS (18) improving the detection rate of PCa located solely in the anterior zone of the gland (about 10% of the cases) (19, 20) . In the last years, mpMRI and mpMRI/TRUS fusion targeted biopsy have a good degree of accuracy in diagnosing clinically significant PCa secondary to the high sensitivity for lesion upgrading, especially when the cancer is located in the anterior prostate (6, 7); mpMRI targeted biopsy allows to reclassify about 10% of patients eligible for AS in comparison with standard trans-rectal biopsy (21, 22) . In addition, if confirmed by larger studies, mpMRI could be useful to better define those having very low risk PCa allowing for a greater interval of time for prostate biopsy re-evaluation (23) and reducing the risk of clinical complications secondary to repeat biopsy (24) . On the other hand, false negative rate of mpMRI in diagnosing significant PCa is equal to 15-30% of the cases especially in the presence of low volume of PCa with GS ≥ 7 (25); in this respect, a combination of systematic and MRI/TRUS fusion targeted cores increase detection on significant PCa (26) (27) (28) .
In our series, we found mpMRI to have a 83.4% (PI-RADS 3-5) diagnostic accuracy rate with a 94.6% NPV rate in predicting the presence of clinically significant PCa; mpMRI/TRUS targeted biopsy and extended biopsy missed 5/21 (23.8%) and 4/21 (19%) significant PCa which were found by SPBx (p = 0.001) being characterised by the presence of a single positive core of GS ≥ 7 with GPC < 10%. These data suggest that mpMRI/TRUS fusion biopsies alone could miss small but significant PCa because mpMRI accuracy significantly correlates with the diameter of the suspicious lesions (7, 29) ; moreover, in a selected population of men with very low-risk PCa in AS with an expected negative mpMRI, the suspicious lesions with PI-RADS 3 should undergo targeted biopsy to improve the reclassification of the patients. In definitive, SPBx detect the highest percentage of PCa allowing to better define the best therapeutic clinical strategy for each patient. Limitations and considerations of the present study need mention. Firstly, a greater number of patients need to be examined; secondly, we do not know the true diagnostic accuracy of mpMRI and biopsy procedure in PCa diagnosis because the detection rate for cancer was compared only in 16/75 (21.3%) cases with definitive specimen. Finally, we cannot establish if the two mpMRI false positives were possibly re-assignable to false-negative repeat prostate biopsy procedures (30) .
In conclusion, although mpMRI improve the diagnosis of clinically significant PCa, SPBx is provided of the best detection rate for PCa in men enrolled in AS protocols who underwent confirmatory biopsy. 
